PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Subjects

Subjects :

Oncology
Sorafenib
medicine.medical_specialty
Second line treatment
business.industry
medicine.medical_treatment
Hematology
medicine.disease
Targeted therapy
Hepatocellular carcinoma
Internal medicine
medicine
In patient
Previously treated
business
medicine.drug

Details

ISSN :

09237534

Volume :

30

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........154d33fc30b2f32359860da7770d3434

Full Text :

https://doi.org/10.1093/annonc/mdz155.384